MGMT非细胞核酸血清学检测联合启动子甲基化实验明显提高替莫唑胺靶向治疗效果的初步研究  

TMZ targeted therapy evaluated by MGMT cfNA combination with MGMT promoter methylation levels

作　　者：袁红平[1] 罗林[1] 左频[1] 倪炜[1] 范耀东[1] 石睿[1] 

机构地区：[1]昆明医学院第三附属医院云南省肿瘤医院神经外科,云南昆明650031

出　　处：《云南医药》2012年第2期106-110,共5页Medicine and Pharmacy of Yunnan

摘　　要：目的探讨O6-甲基鸟氨酸DNA甲基转移酶(Methylation Ganinine Methylate Tranmethylases,MGMT)非细胞核酸血清学检测联合启动子甲基化实验对提高替莫唑胺(Temozolomide,TMZ)临床治疗效果的新的方法学。方法应用现代先进的实时定量PCR技术,在血液样本中鉴定MGMT基因来源的非细胞核酸,同时对手术中获得的肿瘤样本进行MGMT基因启动子甲基化修饰检查。最后结合两者的结果鉴定患者是否有条件接受TMZ的化疗。结果我们检测到27例为甲基化特异性(Methylation specific PCR,MSP)阴性同时非细胞核酸(cell free nucleoacid,cfNA)也为阴性,22例MSP阴性cfNA同时阳性,19例MSP阳性cfNA也为阳性。在临床治疗中cfNA阳性是TMZ治疗的关键决定因素。结论通过这一方法学上的改进我们为更多的病人找回了TMZ的化疗机会,提高了胶质母细胞瘤(Glioblastoma,GBM)肿瘤病人的治疗效果。objective To investigate the new method of TMZ targeted therapy evaluated by MGMT cfNA combination with MGMT promoter methylation levels.Methods： Taking the advantage of powerful and easily cell-free nucleic acids（cfNA） testing,we developed a new method for MGMT test which is combination of evaluation the promoter methylation levels in GBM samples and MGMT cfNA in the blood circulation of GBM patients.Results： 27 cases were determined as MSP negative/cfNA negative,22 cases were detected as MSP negative/cfNA positive and 19 cases were evaluated as MSP positive/cfNA positive.The cfNA positive was the determine factor for TMZ response.Conclusion： Relying on this relatively comprehensive method the drug sensitivity experiment of temozolomide was proved a lot.The improvment does help a vast group of GBM patients to gain temozolomide therapy opportunity.

关 键 词：胶质母细胞瘤 甲基化特异PCR RT-PCR 

分 类 号：R730.264[医药卫生—肿瘤]